Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
2026-05-19 13:37:19 ET
On May 15, 2026, Saturn V Capital Management LP disclosed in an SEC filing that it sold 822,007 shares of Dyne Therapeutics (NASDAQ:DYN) , an estimated $14.17 million transaction based on quarterly average pricing.
According to a May 15, 2026, SEC filing , Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics during the first quarter. The estimated transaction value, based on the quarter’s average closing price, was $14.17 million. The fund finished the period with 966,609 shares, while the quarter-end value of its Dyne Therapeutics stake decreased by $17.46 million, a change that includes both sales and market price effects.
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel therapeutics for rare, genetically driven muscle diseases. The company leverages its FORCE platform to design targeted therapies with the aim of delivering disease-modifying benefits for underserved patient populations. Dyne's strategic focus on rare muscle disorders positions it to address significant unmet medical needs and build a competitive edge in the biotechnology sector.
NASDAQ: DYN
DYN Trading
-4.49% G/L:
$17.67 Last:
380,202 Volume:
$18.09 Open:
